This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Join PATH in Seattle at the 2022 American Society of Tropical Medicine & Hygiene Annual Meeting

October 17, 2022 by PATH

From October 30 to November 3, 2022, the annual meeting of the American Society of Tropical Medicine & Hygiene (ASTMH) returns to an in-person format after being held virtually in 2020 and 2021.

The five-day international forum—held this year at the Seattle Convention Center—provides an opportunity for the global health community to share their latest work. At PATH, we support a wide breadth of malaria control and elimination efforts rooted in deep technical expertise, ranging from accelerating malaria vaccine development and introduction, advancing vector control, improving diagnostic tests, expanding access to existing and new tools, and developing, evaluating, and scaling digital platforms to inform decision-making. PATH’s malaria work will be on display across 35 presentations at the annual meeting through symposia, oral presentations, poster presentations, and side events.

Among the presentations to be delivered by PATH this year are evaluations of malaria surveillance systems in multiple countries, a case study on the resilience of community health workers in Zambia during the COVID-19 pandemic, assessments of diagnostics such as point-of-care tests for glucose-6-phosphate dehydrogenase deficiency, and evaluations of the efficacy of novel dual active ingredient insecticide-treated nets across a variety of settings in sub-Saharan Africa. And at this year’s conference, PATH and partners will present the latest on RTS,S/AS01—which last year became the first malaria vaccine and first vaccine to combat a human parasite to be recommended by the World Health Organization—including evidence and experiences in pilot areas, the vaccine’s efficacy according to various dose regimens, and its duration of protection when used in combination with seasonal malaria chemoprevention.

In addition to displaying our latest findings, these presentations reflect PATH’s commitment to partnership and innovative, data-driven solutions. We are excited to share our work, and we hope you will join us at this year’s ASTMH events.

Follow the conversation online at #Tropmed2022 or via @PATHTweets, and @PATHMalaria.

Times for all ASTMH events are in Pacific Time.

See below for a full schedule of PATH’s symposia, oral presentations, posters, and side events at the conference.

Symposia

ANC Surveillance: An Old Platform for New Uses?

When: Monday, Oct 31, 8:00 a.m.

Where: Convention Center, Room 618/619/620 (6th Floor)

This presentation explores the potential of antenatal care (ANC)-based surveillance to monitor malaria prevalence and coverage indicators, measure burden, and monitor trends among pregnant women—building on the strengths and minimizing the limitations of other commonly employed surveillance approaches. If pregnant women attending their first ANC visit prove a reliable sentinel population for trends at the community level, the programmatic implications are significant—ranging from reducing the need for expensive household surveys to informing program managers of micro-level coverage trends, better enabling data-based decisions to adapt implementation and resource application. Diverse sub-Saharan African countries will share pilot ANC surveillance data highlighting the correlation between data collected from pregnant women attending ANC visits and household survey data for parasitemia and coverage of malaria control interventions. Feasibility of implementing ANC surveillance will be discussed across endemic and pandemic diseases.

Structural characterization of protective epitopes in P. falciparum CSP

When: Monday, October 31, 8:25 a.m.

Where: Convention Center, Room 6C (6th Floor)

This presentation will share the structural characteristics of protective and non-protective monoclonal antibodies to the circumsporozoite protein (CSP) at a molecular level from crystallography and other biophysical analysis methodologies. Further, key features of protective responses can be gleaned from these data, their application to understanding polyclonal responses, and toward the design of next-generation malaria vaccines.

New Dual-AI Nets for Malaria Control in Settings of Vector Resistance: A Review of the Current Evidence

When: Monday, Oct 31, 3:00 p.m.

Where: Convention Center, Room 605/610 (6th Floor)

This symposium will examine the growing evidence base for the efficacy and cost-effectiveness of novel dual active ingredient (AI) insecticide-treated nets (ITNs) in comparison to standard, pyrethroid-only ITNs. There will be four key components: presenting the latest evidence of efficacy from two randomized control trials (Benin and Tanzania), presenting the latest evidence from the New Nets Project pilot evaluations (Burkina Faso, Mozambique, Rwanda, Nigeria, and Mali), discussion of the latest advances in mathematical modelling of vector control impact and cost-effectiveness, and a presentation highlighting key issues surrounding the market dynamics and anticipated demand for dual-AI ITNs. Taken together, the evidence assessed here will provide key information for malaria control programs, donors, policymakers, and other stakeholders for decision-making and planning future strategies on where these new tools are likely to be most effective—improving access, uptake, and utilization in varied operational contexts.

Scaling up the World's First Malaria Vaccine Recommended for Use

When: Monday, Oct 31, 5:15 p.m.

Where: Convention Center, Room 605/610 (6th Floor)

In this symposium, presenters will highlight evidence and experiences from Ghana, Kenya, and Malawi, the three countries that introduced the RTS,S malaria vaccine through pilot implementation. Evidence generated through this pilot program was considered by strategic advisory groups to the World Health Organization in 2021, when RTS,S/AS01 became the first malaria vaccine to receive a recommendation to reduce child illness and deaths from malaria in sub-Saharan Africa and other regions with moderate to high Plasmodium falciparum transmission. The symposium will also look beyond the pilot countries and include a presentation of the framework to allocate the initial limited supply of the vaccine and efforts to accelerate access to this lifesaving vaccine. Finally, the audience will hear what is on the horizon for RTS,S and how lessons learned may be used for future malaria vaccines.

Vaccines that Interrupt Malaria Transmission (VIMT) – Development, Evaluation and Implementation

When: Wednesday, Nov 2, 12:45 p.m.

Where: Convention Center, Room 602/603/604 (6th Floor)

This symposium plans to address key questions about vaccines that interrupt malaria transmission (VIMT): regulatory and implementation pathways, identification of immunological and entomological vaccine-induced endpoints, applicability to other Plasmodium species, and how VIMT success is defined. Each presenter will provide an overview on prior experience exploring some these concepts in prior and current projects, but also will discuss important concepts to explore in future VIMT clinical trials.

Oral presentations

596: Effectiveness of reactive focal mass drug administration for malaria in Thailand during the COVID-19 pandemic

When: Monday, Oct 31, 4:15 p.m.

Where: Convention Center, Room 6AB (6th Floor)

Presenter: Adam Bennett, Senior Scientific Advisor, PATH

597: Feasibility and effectiveness of targeted malaria interventions for high-risk populations in Senegal

When: Monday, Oct 31, 4:30 p.m.

Where: Convention Center, Room 6AB (6th Floor)

Presenter: Sarah Gallalee, University of California San Francisco Malaria Elimination Initiative

LB-5495: Preliminary results of the New Nets Project pilot evaluations in Mozambique: Epidemiological trends through twelve months

When: Wednesday, Nov 2, 12:15 p.m.

Where: Convention Center, Room 6AB (6th Floor)

Presenter: Joseph Wagman, Project Director of the New Nets Project, PATH

1782: The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention, versus either intervention given alone

When: Thursday, Nov 3, 8:00 a.m.

Where: Convention Center, Room 6AB (6th Floor)

Presenter: Matthew Cairns, London School of Hygiene & Tropical Medicine

1817: Proactive community malaria case management: Ongoing randomized control trial in Chadiza District, Eastern Province, Zambia

When: Thursday, Nov 3, 8:00 a.m.

Where: Convention Center, Room 608/609 (6th Floor)

Presenter: Marie-Reine Rutagwera, Strategic Information Advisor of PAMO Plus, PATH

Poster presentations

Poster Session A, Monday, Oct 31, 11 a.m. to 12:45 p.m.

250: Performance and usability evaluation of point-of-care tests for glucose-6-phosphate dehydrogenase deficiency in Mae Sot, Thailand

Presenter: Stephanie Zobrist, Program Officer, PATH

284: Defining malaria operational research and program evaluation priorities for sub-Saharan Africa: Results from a broad stakeholder consultation process

Presenter: Roger Tine, Université Cheikh Anta Diop

285: Community health worker resilience in the fight against malaria amidst COVID-19: A case study from Eastern Province, Zambia

Presenter: Marie-Reine Rutagwera, Strategic Information Advisor PAMO Plus, PATH

393: Seasonal vaccination with the RTS,S/AS01E malaria vaccine given with or without seasonal malaria chemoprevention: extension of a randomized, double-blind Phase 3 trial until children reach the age of five years

Presenter: Jean-Bosco Ouedraogo, INSTech

409: Effect of deltamethrin-piperonyl butoxide (PBO) insecticide-treated nets on malaria case incidence and entomological indicators in Ebonyi, Nigeria

Presenter: Kelly M. Davis, Impact Evaluation and Data Associate, PATH

LB-5126: Efficacy of the RTS,S/AS01E malaria vaccine administered according to different fractional and full dose regimens under conditions of natural exposure in African children aged 5-17 months: First genotyping-based endpoint results from a phase 2b

Presenter: Michal Juraska, Fred Hutchinson Cancer Center

Poster Session B, Tuesday, November 1, noon to 1:45 p.m.

881: A longitudinal analysis of HRP2 and pLDH antigen dynamics in a cohort of malaria infected individuals from Namibia

Presenter: William N. Sheahan, Research Associate, PATH

925: Using gravity models to estimate facility-level catchment populations and malaria incidence rates from health surveillance systems

Presenter: Justin Millar, Research Scientist, PATH

1010: Efficacy and impact of the RTS,S/AS01E malaria vaccine administered according to different fractional and full dose regimens under conditions of natural exposure in African children: Interim results from a phase 2b randomized controlled trial up to month 32

Presenter: Nelli Westercamp, Centers for Disease Control and Prevention

LB-5289: Estimating the malaria prevention impact of new nets: epidemiological results from piloted dual active ingredient insecticide-treated net distribution in Nigeria

Presenter: Okefu Oyale Okoko, National Malaria Elimination Programme, Federal Ministry of Health Nigeria

LB-5291: Three-years (2019-2021) longitudinal monitoring of malaria transmission intensity in three health districts of Burkina Faso with standard, PBO, and dual active ingredient ITN deployment

Presenter: Madou Tapsoba, Centre National de Recherche et de Formation sur le Paludisme

LB-5292: Evaluating new dual active ingredient insecticide-treated nets in Nigeria: use, access, and barriers

Presenter: Sylvanus Otikwu, Ibolda Health International

LB-5293: Malaria prevention: evaluation of the reasons for non-use of dual active ingredient insecticide-treated mosquito nets in three health districts: Banfora, Gaoua and Orodara in Burkina Faso

Presenter: Moubassira Kagone, Centre National de Recherche et de Formation sur le Paludisme

LB-5294: Determinants of dual active ingredient and PBO insecticide-treated net utilization in Mozambique, Nigeria, and Burkina Faso

Presenter: Julia Mwesigwa, Senior Research Officer, PATH

LB-5296: Effects of dual active ingredient insecticide-treated bed nets on malaria prevalence in children aged 6-59 months: Preliminary results of a pilot study in Burkina Faso

Presenter: Harouna Soré, Centre National de Recherche et de Formation sur le Paludisme

LB-5297: New, dual-active ingredient insecticide-treated nets in Rwanda: access, use and barriers

Presenter: Chantal M. Ingabire, University of Rwanda

LB-5312: Emerging evidence from large controlled human malaria infection trials supports previously identified RTS,S biomarkers associated with protection

Presenter: Rachel L. Spreng, Duke University

Poster Session C, Wednesday, Nov 2, 11:00 a.m. to 12:45 p.m.

1489: Quantifying seasonal migration and its effects on malaria transmission in districts of high, moderate, and low risk in Ethiopia

Presenter: Amir Siraj, Research and Data Analyst, PATH

1503: Evaluating the malaria surveillance system in the Democratic Republic of Congo for strengthening surveillance and efficient malaria control

Presenter: Alain Bokota, National Malaria Control Program, Ministry of Health, Democratic Republic of the Congo

1553: Interpersonal communication: An effective approach in boosting and sustaining uptake of malaria services and products in Kanchibiya District, Zambia

Presenter: Elizabeth Chiyende, Social Behavior Change Specialist, PATH

1603: Evaluating the impact of indoor residual spraying on malaria transmission in Madagascar using existing data sources

Presenter: Emily R. Hilton, Research Associate, PATH

LB-5420: Observational analysis to evaluate the impact of new nets in Rwanda: Epidemiological results from piloted new net distributions

Presenter: Julia Mwesigwa, Senior Research Officer, PATH

LB-5422: Incremental cost of the switch from standard insecticide-treated nets (ITNs) to next generation ITNs: an economic evaluation

Presenter: Riley Santiago, Tulane University School of Public Health and Tropical Medicine

LB-5423: Assessment of the Malaria Surveillance System in Nigeria

Presenter: Smita Das, Surveillance Monitoring and Evaluation Officer, PATH

LB-5425: Comparison of malaria infection level in pregnant women with estimates obtained from cross-sectional surveys among children, 2020-2022, Burkina Faso

Presenter: Réné Kinda, Centre National de Recherche et de Formation sur le Paludisme

LB-5444: Last Kilometer Care: Building Powerful Partnerships to Eliminate Malaria

Presenter: Busiku Hamainza, National Malaria Elimination Centre, Zambia

Side event

Paving the way to elimination by optimizing P. vivax radical cure

When: Oct 31, 7:30 p.m. to 9:30 p.m.

Where: Convention Center (contact pave@path.org for more details)

This side event will highlight the work of the Tafenoquine Roll-out STudy (TRuST) with point-of-care glucose-6-phosphate dehydrogenase testing, tafenoquine, and primaquine in the Brazilian Amazon. Principal investigator (PI) and co-PI of the study, Drs. Marcus Lacerda from Tropical Medicine Foundation and Dhelio Pereira from Centro de Pesquisa em Medicina Tropical, will present the key findings and experience from TRuST. Then, Dr. Keoboupaphone Chindavongsa from Center for Malaria, Parasitology, and Entomology in Lao PDR will present on the experience and learnings from the nationwide rollout in Lao PDR of point-of-care G6PD testing. The event will conclude with an open, moderated discussion.

PATH Malaria focuses on developing, introducing, and evaluating new tools and approaches; optimizing the delivery of current tools and approaches; improving data use through enhanced measurement tools, metrics, and information systems; and strengthening endemic country expertise to create sustainable systems.

Learn more about our malaria work